Regulus Therapeutics Inc.
RGLS
Clasificación en acciones
#17332
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Precio por acción
$8.16
Última sincronización: 2025-06-26
Capitalización bursátil
$234.57M
Cambio (1 día)
0.00%
Cambio (1 año)
-88.86%
País
US
Comercio Regulus Therapeutics Inc. (RGLS)
Categoría
Healthcare
Ratio P/B de Regulus Therapeutics Inc. (RGLS)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Regulus Therapeutics Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Regulus Therapeutics Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
